NEW YORK (GenomeWeb News) – Rosetta Genomics today announced a credentialing agreement with managed care firm Prime Health Services to cover Rosetta's miRview mets2 test.

The deal is the first between Rosetta and a US preferred provider organization, Rosetta said. As a result, the number of covered lives having access to miRview mets2 as an in-network service totals more than 6.5 million.

The miRview mets2 assay is a microRNA-based assay for identifying the tumor of origin in cancers of unknown or uncertain primary.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.